English
Home > Products > 147098-20-2

China 147098-20-2 Factory

Our development depends on the advanced equipment, excellent talents and continuously strengthened technology forces for 147098-20-2,CAS NO 147098-20-2,Rosuvastatin API,Rosuvastatin calcium, Presently, we are looking forward to even larger cooperation with overseas clients based on mutual benefits. Make sure you come to feel no cost to make contact with us for more information.
147098-20-2, Taking the core concept of "to be the Responsible". We will redound up on society for high quality solutions and good service. We are going to initiative to participate in international competition to be a first- class manufacturer of this product in the world.

Related Products

Hot Products

  • Hexamethonium bromide

    Hexamethonium bromide

    Product Name:Hexamethonium bromide
    Molecular Formula:C12H30Br2N2
    Molecular Weight:362.19
    CAS Registry Number:55-97-0
  • 4-Bromo-2,6-difluoroaniline

    4-Bromo-2,6-difluoroaniline

    Product Name:4-Bromo-2,6-difluoroaniline
    Molecular Formula:C6H4BrF2N
    Molecular Weight:208
    CAS Registry Number:67567-26-4
  • Borane tert-butylamine complex

    Borane tert-butylamine complex

    Product Name:Borane tert-butylamine complex
    Molecular Formula:C4H11BN
    Molecular Weight:83.94784
    CAS Registry Number:7337-45-3
  • Etamsylate

    Etamsylate

    Product Name:Etamsylate
    Molecular Formula:C10H17NO5S
    Molecular Weight;263.31
    CAS Registry Number;2624-44-4
  • Olprinone Hydrochloride

    Olprinone Hydrochloride

    Product Name:Olprinone Hydrochloride
    Molecular Formula:C14H11ClN4O
    Molecular Weight;286.72
    CAS Registry Number;119615-63-3
  • Estradiol Cypionate

    Estradiol Cypionate

    Product Name:Estradiol Cypionate
    Molecular Formula:C26H36O3
    Molecular Weight:396.57
    CAS Registry Number;313-06-4
  • Related Blog
  • Reviews

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • What is an Active Pharmaceutical Ingredient (API in Pharma)?

    Sandoo Pharmaceutical is a professional active pharmaceutical intermediate manufacturer, producing high quality APIs. Sandoo Pharmaceutical provides a wide range of active pharmaceutical intermediates.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    Here are so many diseases that affect the human population in the current hours and so are the numerous drugs that are available to treat those diseases.

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 147098-20-2

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept